JP2024514308A5 - - Google Patents

Info

Publication number
JP2024514308A5
JP2024514308A5 JP2023560349A JP2023560349A JP2024514308A5 JP 2024514308 A5 JP2024514308 A5 JP 2024514308A5 JP 2023560349 A JP2023560349 A JP 2023560349A JP 2023560349 A JP2023560349 A JP 2023560349A JP 2024514308 A5 JP2024514308 A5 JP 2024514308A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
domain
molecule according
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514308A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/022575 external-priority patent/WO2022212525A2/en
Publication of JP2024514308A publication Critical patent/JP2024514308A/ja
Publication of JP2024514308A5 publication Critical patent/JP2024514308A5/ja
Pending legal-status Critical Current

Links

JP2023560349A 2021-03-30 2022-03-30 CAR T細胞療法及びIFNγ Pending JP2024514308A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163168210P 2021-03-30 2021-03-30
US63/168,210 2021-03-30
PCT/US2022/022575 WO2022212525A2 (en) 2021-03-30 2022-03-30 Car t cell therapy and ifn gamma

Publications (2)

Publication Number Publication Date
JP2024514308A JP2024514308A (ja) 2024-04-01
JP2024514308A5 true JP2024514308A5 (cg-RX-API-DMAC7.html) 2025-04-08

Family

ID=81384825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560349A Pending JP2024514308A (ja) 2021-03-30 2022-03-30 CAR T細胞療法及びIFNγ

Country Status (5)

Country Link
US (1) US20240366662A1 (cg-RX-API-DMAC7.html)
EP (1) EP4314040A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024514308A (cg-RX-API-DMAC7.html)
CN (1) CN117242090A (cg-RX-API-DMAC7.html)
WO (1) WO2022212525A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025235801A1 (en) 2024-05-08 2025-11-13 City Of Hope Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2735456C (en) * 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
CN107074957B (zh) * 2014-01-13 2021-05-07 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
ES2738705T3 (es) 2014-09-19 2020-01-24 Hope City Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2
CN107429253B (zh) * 2014-12-05 2021-11-05 希望之城公司 Cs1靶向性嵌合抗原受体修饰的t细胞
EP3747462A1 (en) 2015-10-06 2020-12-09 City of Hope Chimeric antigen receptors targeted to psca
JP7085990B2 (ja) * 2015-10-13 2022-06-17 シティ・オブ・ホープ クロロトキシンドメインを含むキメラ抗原レセプター
ES2909973T3 (es) 2015-11-04 2022-05-10 Hope City Receptores quiméricos para el antígeno que se dirigen a HER2
JP7189019B2 (ja) * 2016-02-05 2022-12-13 シティ・オブ・ホープ 中枢神経系の癌の治療のための操作されたt細胞の投与
WO2019148006A1 (en) * 2018-01-26 2019-08-01 City Of Hope Chimeric antigen receptors and methods for reducing off target toxicity
US12410226B2 (en) 2018-07-30 2025-09-09 The Board Of Trustees Of The Leland Stanford Junior University Interferon-gamma biased agonists
EP3830133A1 (en) * 2018-08-01 2021-06-09 City of Hope Tag72 targeted chimeric antigen receptor modified t cells for treatment of tag72-positive tumors
US10918667B2 (en) * 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
WO2021179967A1 (zh) * 2020-03-09 2021-09-16 四川大学华西医院 IFN-γ在制备抗肿瘤辅助药物中的应用
EP4118106A1 (en) * 2020-03-12 2023-01-18 City of Hope TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Ralpha2 POSITIVE MALIGNANCIES

Similar Documents

Publication Publication Date Title
JP2021530217A5 (cg-RX-API-DMAC7.html)
US20240307440A1 (en) Cell expressing a car and a transcription factor and its use
JP2023071729A5 (cg-RX-API-DMAC7.html)
CN107406518B (zh) 嵌合抗原受体
JP7492561B2 (ja) ヒト化bcma抗体およびbcma-car-t細胞
JP2023527049A5 (cg-RX-API-DMAC7.html)
JP2023139070A5 (cg-RX-API-DMAC7.html)
JP2022109953A5 (cg-RX-API-DMAC7.html)
JP7395249B2 (ja) 細胞
EP3472205B1 (en) Chimeric antigen receptor
ES2329334T3 (es) Formas multimericas de ligandos de la superfamilia de tnf.
AU776825B2 (en) Molecules designated LDCAM
JP2019517267A5 (cg-RX-API-DMAC7.html)
JP2022541657A5 (cg-RX-API-DMAC7.html)
JP2021525534A5 (cg-RX-API-DMAC7.html)
JP2021512615A5 (cg-RX-API-DMAC7.html)
JPH08507676A (ja) 可溶性オリゴマー蛋白質の調製法
JP2002521053A (ja) ヘテロミニ体
KR20220025698A (ko) 다기능 융합 단백질 및 이의 용도
JP2007519611A (ja) 分泌された三量体受容体類似体及び生物学的活性融合タンパク質を製造するための方法及び組成物
JP2022545815A5 (cg-RX-API-DMAC7.html)
WO2018199595A1 (ko) 4-1bbl 변이체 및 이를 포함하는 융합 단백질
JP2023524132A5 (cg-RX-API-DMAC7.html)
JP2022548866A5 (cg-RX-API-DMAC7.html)
JP2025108507A (ja) Dap10/dap12融合ポリペプチド